References
Appelbaum, F. R., Gundacker, H., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., … Petersdorf, S. H. (2006). Age and acute myeloid leukemia. Blood, 107, 3481-3485. doi: 10.1182/blood-2005-09-3724
Aribi, A., Ravandi, F., & Giles, F. (2006). Novel agents in acute myeloid leukemia. Cancer Journal, 12, 77-91.
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R., & Sultan, C. (1985). Proposed revised criteria for the classification of acute myeloid leukemia. The French-American-British Cooperative Group. Annals of Internal Medicine, 103, 620-625.
Buchner, T., Berdel, W. E., Wormann, B., Schoch, C., Haferlach, T., Schnittger, S., … Hiddemann, W. (2005). Treatment of older patients with AML. Critical Reviews in Oncology/Hematology, 56, 247-259. doi: 10.1016/j.critrevonc.2004.09.010
Burnett, A. K., & Mohite, U. (2006). Treatment of older patients with acute myeloid leukemia—New agents. Seminars in Hematology, 43, 96-106. doi: 10.1053/j.seminhematol.2006.01.003
Byrd, J. C., Mrozek, K., Dodge, R. K., Carroll, A. J., Edwards, C. G., Arthur, D. C., … Cancer and Leukemia Group B (CALGB 8461). (2002). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100, 4325-4336.
Cashen, A., Schiller, G., Larsen, J., Cullen, M. T., DiPersio, J. F. (2006). Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML). ASH Annual Meeting Abstracts, 108, 1984.
de la Serna, J., Montesinos, P., Vellenga, E., Rayón, C., Parody, R., León, A, … Sanz, M. A. (2008). Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 111, 3395-3402. doi: 10.1182/blood-2007-07-100669
Deschler, B., & Lubbert, M. (2006). Acute myeloid leukemia: Epidemiology and etiology. Cancer, 107, 2099-2107. doi: 10.1002/cncr.22233
Döhner, K., & Döhner, H. (2008). Molecular characterization of acute myeloid leukemia. Haematologica, 93, 976-982. doi: 10.3324/haematol.13345
Epstein, J. B., & Schubert, M. M. (1999). Oral mucositis in myelosuppressive cancer therapy. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 88, 273-276. doi: 10.1016/S1079-2104(99)70026-0
Estey, E. (2006). General approach to and perspectives on clinical research in older patients with newly diagnosed acute myeloid leukemia. Seminars in Hematology, 43, 89-95. doi: 10.1053/j.seminhematol.2006.01.002
Estey, E. (2007). Acute myeloid leukemia and myelodysplastic syndromes in older patients. Journal of Clinical Oncology, 25, 1908-1915. doi: 10.1200/JCO.2006.10.2731
Estey, E., & Döhner, H. (2006). Acute myeloid leukemia. Lancet, 368, 1894-1907. doi: 10.1016/S0140-6736(06)69780-8
Farag, S. S., Archer, K. J., Mrozek, K., Ruppert, A. S., Carroll, A. J., Cardiman, J. W., … Bloomfield, C. D. (2006). Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood, 108, 63-73. doi: 10.1182/blood-2005-11-4354
Geller, R. B. (1996). Use of cytokines in the treatment of acute myelocytic leukemia: A critical review. Journal of Clinical Oncology, 14, 1371-1382.
Giles, F. J., Kantarjian, H. M., Kornblau, S. M., Thomas, D. A., Garci-Manero, G., Waddelow, T. A., … Estey, E. H. (2001). Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer, 92, 406-413. doi: 10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U
Greiner, J., Döhner, H., & Schmitt, M. (2006). Cancer vaccines for patients with acute myeloid leukemia—Definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica, 91, 1653-1661.
Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S., Harrison, C. J., … Medical Research Council Adult Leukemia Working Party. (2001). The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia: Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 98, 1312-1320. doi: 10.1182/blood.V98.5.1312
Harris, D. J., Eilers, J., Harriman, A., Cashavelly, B. J., & Maxwell, C. (2008). Putting Evidence Into Practice: Evidence-based interventions for the management of oral mucositis. Clinical Journal of Oncology Nursing, 12, 141-152. doi: 10.1188/08.CJON.141-152
Harris, D. J., & Knobf, M. T. (2004). Assessing and managing chemotherapy-induced mucositis pain. Clinical Journal of Oncology Nursing, 8, 622-627. doi: 10.1188/04.CJON.622-628
Harris, N., Jaffe, E., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., … Bloomfield, C. D. (1999). World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Journal of Clinical Oncology, 17, 3835-3849. Retrieved from
http://jco.ascopubs.org/cgi/content/full/17/12/3835 http://jco.ascopubs.org/cgi/content/full/17/12/3835
Higa, G. M., Gockerman, J. P., Hunt, A. L., Jones, M. R., & Horne, B. J. (1991). The use of prophylactic eye drops during high-dose cytosine arabinoside. Cancer, 68, 1691-1693.
Jabbour, E. J., Estey, E., & Kantarjian, H. M. (2006). Adult acute myeloid leukemia. Mayo Clinic Proceedings, 81, 247-260. doi: 10.4065/81.2.247
Jackson, G. H., & Taylor, P. R. A. (2002). Acute myeloid leukaemia: Optimising treatment in elderly patients. Drugs and Aging, 19, 571-581. doi: 10.2165/00002512-200219080-00003
Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., … Estey, E. (2006). Results of intensive chemotherapy in 998 patients age 65 or older with acute myeloid leukemia or high-risk myelo-dysplastic syndrome: Predictive prognostic models for outcome. Cancer, 106, 1090-1098. doi: 10.1002/cncr.21723
King, M., & Rowe, J. (2007). Recent developments in acute myelogenous leukemia therapy. Oncologist, 12(Suppl. 2), 14-21.
Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A., … Linch, D. C. (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-1759.
Leith, C. P., Kopecky, K. J., Chen, I. M., Eijdems, L., Slovak, M. L., McConnell, T. S., … Willman, C. L. (1999). Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood, 94, 1086-1099.
Lowenberg, B., Boogaerts, M., Daenen, S., Verhoef, G. E., Hagenbeek, A., Vellenga, E., … van Putten, W. L. (1997). Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during and after induction therapy of acute myeloid leukemia. Journal of Clinical Oncology, 15, 3496-3506.
Lowenberg, B., Suciu, S., Archimbaud, E., Ossenkoppele, G., Verhoef, G. E., Vellegna, E., … Zittoun, R. (1997). Use of recombinant GMCSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Group. Blood, 90, 2952-2961.
Lubbert, M., Rüter, B., Claus, R., Schmid, M., Germing U., & Eimermacher, H. (2007). Continued low-dose decitabine is an active first line treatment in all cytogenetic subgroups of older AML patients: Results of the FR00331 multicenter phase II study [Abstract]. Blood, 110, 300.
Markovic, A., MacKenzie, K. L., & Lock, R. B. (2005). FLT-3: A new focus in the understanding of acute leukemia. International Journal of Biochemistry and Cell Biology, 37, 1168-1172. doi: 10.1016/j.biocel.2004.12.005
Mayer, R., Davis, R., Schiffer, C., Berg, D. T., Powell, B. L., Schulman, P., … Frei, E., III. (1994). Intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine, 331, 896-903. doi: 10.1056/NEJM199410063311402
Melchert, M. (2006). Managing acute myeloid leukemia in the elderly. Oncology, 20, 1674-1682.
Mrózek, K., Marcucci, G., Paschka, P., Whitman, S. P., & Bloomfield, C. D. (2007). Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood, 109, 431-448. doi: 10.1182/blood-2006-06-001149
Ohno, R., Naoe, T., Kanamaru, A., Yoshida, M., Hiraoka, A., Kobayashi, T., … Saito, Y. (1994). A double-blind controlled study of granulocyte- stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia: Kohseisho Leukemia Study Group. Blood, 83, 2086-2092. Retrieved from
http://bloodjournal.hematologylibrary.org/cgi/reprint/83/8/2086 http://bloodjournal.hematologylibrary.org/cgi/reprint/83/8/2086
Pinto, A., Zagonel, V., & Ferrara, F. (2001). Acute myeloid leukemia in the elderly: Biology and therapeutic strategies. Critical Reviews in Oncology/Hematology, 39, 275-287. doi: 10.1016/S1040-8428(00)00122-0
Redaelli, A., Stephens, J. M., Brandt, S., Botteman, M. F., & Pashos, C. L. (2004). Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treatment Reviews, 30, 103-117. doi: 10.1016/S0305-7372(03)00142-7
Sanz, M., Tallman, M., & Lo-Coco, F. (2005). Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemia. Oncologist, 10, 806-814. doi: 10.1634/theoncologist.10-10-806
Sekeres, M. A. (2006). Non-transplant therapy for older adults with acute myeloid leukemia. Journal of the National Comprehensive Cancer Network, 4, 51-56.
Sekeres, M. A., & Stone, R. M. (2002). The challenge of acute myeloid leukemia in older patients. Current Opinion in Oncology, 14, 24-30. doi: 10.1097/00001622-200201000-00005
Sekeres, M. A., Stone, R. M., Zahrieh, D., Morrison, V., DeAngelo, D. J., Galinsky, I., & Lee, S. J. (2004). Decision-making and quality of life in older adults with AML or advanced MDS. Leukemia, 18, 809-816. doi: 10.1038/sj.leu.2403289
Simpson, J. K., & Rosenzweig, M. Q. (2002). Treatment considerations for the elderly person with cancer. AACN Clinical Issues, 13, 43-60. doi: 10.1097/00044067-200202000-00006
Stock, W. (2006). Controversies in treatment of AML: Case-based discussion. Hematology, 185-191.
Stone, R. M. (2002). The difficult problem of acute myeloid leukemia in the older adult. CA: A Cancer Journal for Clinicians, 52, 363-371. doi: 10.3322/canjclin.52.6.363
Sudan, N., Rossetti, J. M., Shadduck, R. K., Latsco, J., Lech, J. A., Kaplan, R. B., … Lister, J. (2006). Treatment of acute myelogenous leukemia with azacitidine. Cancer, 107, 1839-1843. doi: 10.1002/cncr.22204
Yancik, R. (1997). Cancer burden in the aged: An epidemiologic and demographic overview. Cancer, 80, 1271-1283.
Zitella, L., Gobel, B., & O'Leary, C. (2009). Prevention of infection. In L. Eaton & J. Tipton (Eds.), Putting Evidence Into Practice: Improving oncology patient outcomes (pp. 267-283). Pittsburgh, PA: Oncology Nursing Society.
Zittoun, R., Suciu, S., Mandelli, F., de White, T., Thaler, J., Stryckmans, P., … Willemze, R. (1996). Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. Journal of Clinical Oncology, 14, 2150-2159.